In recent years, advances in our understanding of inflammatory mediators and the underlying pathogenesis of psoriasis and psoriatic arthritis have shed light on potential therapeutic targets, which has led to the development of several new promising treatments. In this article, key clinical trials, mechanisms of action, patient outcomes, and relevant safety information for these novel topical medications will be evaluated. This article is the first in a 3-part series on treatments presently in the pipeline for the management of psoriasis and psoriatic arthritis including topical agents, biologic treatments, and systemic therapies in phase 2 and phase 3 clinical trials. With novel approaches to the disease process, these therapies may afford more targeted individualized treatment regimens and offer hope to patients with psoriasis and psoriatic arthritis who have reported a suboptimal therapeutic response to conventional therapies.

Topical therapies are a mainstay in the management of patients with mild to moderate psoriasis (Figure). Presently, US Food and Drug Administration–approved topical medications that are commercially available for use in patients with psoriasis include corticosteroids, vitamin D3 analogues, calcineurin inhibitors, retinoids, anthralin, and tar-based formulations. In recent years, research has furthered our understanding of the molecular mechanisms underlying the pathogenesis of psoriasis and has afforded the development of more targeted therapies. Novel topical medications currently in phase 2 and phase 3 clinical trials are discussed in this article, and a summary is provided in the Table.

From the Department of Dermatology, Mount Sinai St. Luke’s-Roosevelt and Beth Israel Medical Centers of the Icahn School of Medicine at Mount Sinai, New York, New York.

Drs. Feely and Smith report no conflict of interest. Dr. Weinberg is a speaker and investigator for LEO Pharma.

This article is the first of a 3-part series. The second part will appear in May 2015.

Correspondence: Meghan A. Feely, MD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke’s-Roosevelt, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025 (mfeely@chpnet.org).
## Novel Topical Therapies for Mild to Moderate Psoriasis Currently in Development

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Manufacturer</th>
<th>Mechanism of Action</th>
<th>Vehicle</th>
<th>Stage of Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>AN2728</td>
<td>Anacor Pharmaceuticals, Inc</td>
<td>PDE4 inhibitor</td>
<td>Ointment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>AS101</td>
<td>BioMAS Ltd</td>
<td>Integrin inhibitor</td>
<td>Cream</td>
<td>Phase 2*</td>
</tr>
<tr>
<td>CP-690,550 (tofacitinib)</td>
<td>Pfizer Inc</td>
<td>Jak1 and Jak3 inhibitor</td>
<td>Ointment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>CT327</td>
<td>Creabilis SA</td>
<td>Tyrosine kinase inhibitor</td>
<td>Cream, ointment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>DPS-101 (calcipotriol and niacinamide)</td>
<td>Dermipsor Ltd</td>
<td>Vitamin D analogue</td>
<td>Cream</td>
<td>Phase 2</td>
</tr>
<tr>
<td>IDP-118 (halobetasol and tazarotene)</td>
<td>Valeant Pharmaceuticals International, Inc</td>
<td>Proprietary steroid and retinoid combination</td>
<td>Lotion</td>
<td>Phase 2</td>
</tr>
<tr>
<td>INC818424 (ruxolitinib)</td>
<td>Incyte Corporation</td>
<td>Jak1 and Jak2 inhibitor</td>
<td>Cream</td>
<td>Phase 2</td>
</tr>
<tr>
<td>LAS41004</td>
<td>Almirall, SA</td>
<td>Proprietary steroid and retinoid combination</td>
<td>Ointment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>LEO 80190c</td>
<td>LEO Pharma</td>
<td>Vitamin D$_3$ analogue and steroid combination</td>
<td>Ointment</td>
<td>Phase 3</td>
</tr>
<tr>
<td>LEO 90100</td>
<td>LEO Pharma</td>
<td>Vitamin D analogue and steroid combination</td>
<td>Cutaneous spray, ointment, aerosol foam</td>
<td>Phase 3</td>
</tr>
<tr>
<td>M518101</td>
<td>Maruho Co, Ltd</td>
<td>Vitamin D analogue</td>
<td>Undisclosed</td>
<td>Phase 3</td>
</tr>
<tr>
<td>MOL4239</td>
<td>Moleculin, LLC</td>
<td>p-STAT3 inhibitor</td>
<td>Ointment</td>
<td>Phase 2</td>
</tr>
<tr>
<td>MOL4249</td>
<td>Moleculin, LLC</td>
<td>p-STAT3 inhibitor</td>
<td>Undisclosed</td>
<td>Phase 3</td>
</tr>
<tr>
<td>MQX-5902 (methotrexate)</td>
<td>MediQuest Therapeutics</td>
<td>Dihydrofolate reductase inhibitor</td>
<td>Proprietary drug delivery formulation</td>
<td>Phase 2</td>
</tr>
<tr>
<td>PH-10</td>
<td>Provectus Biopharmaceuticals, Inc</td>
<td>Xanthine dye</td>
<td>Aqueous hydrogel</td>
<td>Phase 2</td>
</tr>
<tr>
<td>STF115469 (calcipotriene)*</td>
<td>GlaxoSmithKline</td>
<td>Vitamin D analogue</td>
<td>Foam</td>
<td>Phase 3</td>
</tr>
<tr>
<td>WBI-1001</td>
<td>Welichem Biotech Inc</td>
<td>Proprietary product that inhibits proinflammatory cytokines</td>
<td>Cream</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

*Abbreviations: PDE4, phosphodiesterase 4; Jak, Janus kinase; p-STAT3, phosphorylated signal transducer and activator of transcription 3.
*As of publication in March 2015.
*Study was withdrawn prior to enrollment.
*Indicated for sensitive areas (eg, face, intertriginous regions).
*Studied in pediatric patients (age range, 2–11 y).
AN2728 (Phosphodiesterase 4 Inhibitor)
AN2728 (Anacor Pharmaceuticals, Inc) is a phosphodiesterase 4 inhibitor that blocks the inactivation of cyclic adenosine monophosphate, resulting in decreased production of inflammatory cytokines (eg, IL-6, IL-12, IL-23, tumor necrosis factor α [TNF-α]).2,3 In a randomized, double-blind, phase 2 clinical trial (N=35), 40% of patients treated with AN2728 ointment 5% reported improvement of more than 2 points in overall target plaque severity score versus 6% of patients treated with vehicle.4 In another randomized, double-blind, dose-response trial of 145 patients, those treated with AN2728 ointment 2% twice daily reported a 60% improvement versus vehicle (least squares mean, −41.5%).5 Two other phase 2 trials (NCT01246583, NCT00678561) assessing the efficacy, safety, tolerability, and pharmacokinetics of tofacitinib ointment in patients with mild to moderate psoriasis have been completed; results were not available at the time of publication.

AS101 (Integrin Inhibitor)
AS101 (BioMAS Ltd), or ammonium trichloro(dioxoethylene-o,o’)-tellurate, acts as stimulator of regulatory T cells and a redox modulator inhibiting the leukocyte integrins α4β1 and α4β7 that enable CD4+ T-cell and macrophage extravasation; it also limits expression of the inflammatory cytokines IL-6 and IL-17.4 A randomized, placebo-controlled, double-blind, phase 2 study evaluating the efficacy of AS101 cream 4% twice daily for 12 weeks was withdrawn prior to enrollment (NCT00788424).

Tofacitinib (Janus Kinase 1 and 3 Inhibitor)
Tofacitinib (formerly known as CP-690,550) (Pfizer Inc) is a selective Janus kinase (Jak) 1 and Jak3 inhibitor that limits expression of cytokines that promote inflammation (eg, IFN-γ) and inhibits helper T cells (T_H17) by downregulating expression of the IL-23 receptor. Epidermal keratinocyte proliferation in psoriasis is activated by T_H17 cells that release IL-17 as well as T_H1 cells that release IFN-γ and tumor necrosis factor. A phase 2a trial showed statistically significant improvement from baseline in the target plaque severity score for tofacitinib ointment 2% (least squares mean, −54.4%) versus vehicle (least squares mean, −41.5%).5 Two other phase 2 trials (NCT01246583, NCT00678561) assessing the efficacy, safety, tolerability, and pharmacokinetics of tofacitinib ointment in patients with mild to moderate psoriasis have been completed; results were not available at the time of publication.

CT327 (Tyrosine Kinase Inhibitor)
CT327 (Creabilis SA) is a tyrosine kinase A (TrkA) inhibitor that affords a novel perspective in the treatment of pruritus by shifting the focus to sensory neurons. In a phase 2b study of 160 patients, a 60% change in the visual analog scale was noted at 8 weeks in the treatment group versus 21% in the placebo group.6 Two other phase 2 studies have been completed, one with a cream formulation of pegylated K252a (NCT00995969) and another with an ointment formulation (NCT01465282); results were not available at the time of publication.

DPS-101 (Vitamin D Analogue)
DPS-101 (Dermipsor Ltd) is a combination of calcipotriol and niacinamide. Calcipotriol is a vitamin D3 analogue that increases IL-10 expression while decreasing IL-8 expression.7 It curbs epidermal keratinocyte proliferation by limiting the expression of polo-like kinase 2 and early growth response-1.8 It also may induce keratinocyte apoptosis.9 Niacinamide is the amide of vitamin B3 and inhibits proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8.10 In a dose-response phase 2b trial of 168 patients,
DPS-101 demonstrated better results than either calcipotriol or niacinamide alone.11

**IDP-118 (Proprietary Steroid and Retinoid Combination)**

IDP-118 (Valant Pharmaceuticals International, Inc) is a combination of halobetasol propionate (HP) 0.01% (a topical corticosteroid) and tazarotene 0.045% (a selective topical retinoid) in a lotion formulation. In isolation, tazarotene is as effective as a mid to highly potent corticosteroid, but irritation may limit its tolerability. The use of combination treatments of mid to highly potent corticosteroids and tazarotene has shown enhanced tolerability and therapeutic efficacy.12 Ongoing studies include a phase 1 trial and a phase 2 trial to evaluate low- and high-strength preparations of IDP-118, respectively (NCT01670513). Another phase 2 trial evaluating the efficacy and safety of IDP-118 lotion (HP 0.01% and tazarotene 0.045%) versus IDP-118 monad HP 0.01% lotion, IDP-118 monad tazarotene 0.045% lotion, and placebo has been completed (NCT02045277); results were not available at the time of publication.

**Ruxolitinib (Jak1 and Jak2 Inhibitor)**

Ruxolitinib (formerly known as INCB18424) (Incyte Corporation) is a selective Jak1 and Jak2 inhibitor. A phase 2 trial of ruxolitinib showed a 53% decline in the score for mean total lesions in patients treated with ruxolitinib phosphate cream 1% (P=.033) versus 54% in those treated with ruxolitinib phosphate cream 1.5% (P=.056) and 32% in those treated with placebo.13 Three other phase 2 studies (NCT00617994, NCT00820950, NCT00778700) have been completed; results were not available at the time of publication.

**LAS41004 (Proprietary Steroid and Retinoid Combination)**

LAS41004 (Almirall, SA) is an ointment containing the corticosteroid betamethasone dipropionate and the retinoid bexarotene that is being evaluated for treatment of mild to moderate psoriasis. Five phase 2 studies (NCT01119339, NCT01283698, NCT01360944, NCT02111499, NCT01462643) have been completed; results were not available at the time of publication. A randomized, double-blind, phase 2a study (NCT02180464) with a left-right design assessing clinical response to LAS41004 versus control in patients with mild to moderate psoriasis was actively recruiting at the time of publication.

**LEO 80190 (Vitamin D3 Analogue and Steroid Combination)**

LEO 80190 (LEO Pharma) is a combination of the vitamin D3 analogue calcipotriol and the corticosteroid hydrocortisone. It was developed as a treatment for sensitive areas such as the face and intertriginous regions. A randomized, investigator-blind, phase 3 trial (NCT00640822) of LEO 80190 ointment versus tacalcitol ointment and placebo once daily for 8 weeks demonstrated controlled disease of the face in 56.8% (183/322) of patients in the LEO 80190 group, 46.4% (147/317) in the tacalcitol group, and 36.3% (37/102) in the placebo group.14 Another phase 2 study (NCT00704262) and 2 phase 3 studies (NCT00691002, NCT01007591) have been completed; results were not available at the time of publication.

**LEO 90100 (Vitamin D Analogue and Steroid Combination)**

LEO 90100 (LEO Pharma) contains the vitamin D3 analogue calcipotriol and the corticosteroid betamethasone. Three phase 2 studies (NCT01347255, NCT01536886, NCT01536938) and a phase 3 study (NCT01866163) examining the efficacy and safety of various vehicles and formulations of LEO 90100 have been completed; results were not available at the time of publication. Another phase 3 study (NCT02132936) is ongoing but not recruiting participants. Other completed studies whose results were not yet available include a phase 1 pharmacodynamic study (NCT01946386), a phase 1 study that used patch testing to assess the degree of skin irritation and sensitization associated with LEO 90100 (NCT01935869), and a phase 2 study examining the impact of LEO 90100 on calcium metabolism and the hypothalamic-pituitary-adrenal axis (NCT01600222).

**M518101 (Vitamin D Analogue)**

M518101 (Maruho Co, Ltd) is a novel topical vitamin D analogue. Phase 1 (NCT01844973) and phase 2 (NCT01300006, NCT00884169) trials evaluating the safety, pharmacokinetics, and efficacy of M518101 have been completed; results were not available at the time of publication. A phase 3 study (NCT01989429) assessing the safety and therapeutic efficacy of M518101 according to changes in the modified psoriasis area and severity index over an 8-week treatment period also has been completed; results were not yet available. Three phase 3 studies assessing the safety and therapeutic efficacy of M518101 are ongoing: one is currently closed to recruitment (NCT01908595) and 2 are actively...
recruiting participants at the time of publication (NCT01878461, NCT01873677).

**MOL4239 and MOL4249 (Phosphorylated Signal Transducer and Activator of Transcription 3 Inhibitors)**

MOL4239 (Moleculin, LLC) is a novel topical agent for use in mild to moderate psoriasis that acts via phosphorylated signal transducer and activator of transcription 3 (p-STAT3) inhibition.\(^5\) The p-STAT3 protein has increased expression in psoriasis.\(^6\) A phase 2 trial of MOL4239 ointment (NCT01826201) has been completed, showing a greater mean (standard deviation) change in the psoriasis severity score in lesions treated at 28 days with MOL4239 ointment 10% (−1.9 [1.45]) versus lesions treated with placebo ointment (−1.5 [1.87]).\(^7\)

MOL4249 (Moleculin, LLC) is more potent than MOL4239 with better lipid solubility. In the MOL4249 subset of a placebo-controlled, double-blind, phase 2a study of 16 patients with mild to moderate psoriasis, 10% (1/10) of patients experienced complete clearance of psoriatic plaques, 30% (3/10) of patients experienced 75% or greater improvement, and 50% (5/10) of patients experienced 50% or greater improvement compared to 17% (1/6) in the placebo group. Currently, a phase 2a contralateral study, a phase 2b psoriasis area and severity index trial, and a phase 3 pivotal trial are planned, according to the manufacturer.\(^8\)

**MQX-5902 (Dihydrofolate Reductase Inhibitor)**

MQX-5902 (MediQuest Therapeutics) is a topical preparation of methotrexate for the treatment of fingernail psoriasis. Methotrexate is a dihydrofolate reductase inhibitor and antimetabolite that inhibits folic acid metabolism, thereby disrupting DNA synthesis.\(^9\) A phase 2b dose-ranging trial (NCT00666354) was designed to assess the therapeutic efficacy and safety of MQX-5902 delivered via a proprietary drug delivery formulation in fingernail psoriasis; the outcome of this trial was not available at the time of publication.

**PH-10 (Xanthine Dye)**

PH-10 (Provectus Biopharmaceuticals, Inc) is a topical aqueous hydrogel derived from rose bengal disodium that may be beneficial in treating skin conditions such as atopic dermatitis and mild to moderate psoriasis. Rose bengal disodium is a hydrophilic xanthine dye with diagnostic utility in ophthalmology and gastroenterology as well as projected use as a melanoma treatment as demonstrated in phase 1 and phase 2 clinical trials of PV-10 (Provectus Biopharmaceuticals, Inc).\(^10\) Two phase 2 studies assessing the safety and therapeutic efficacy of PH-10 in psoriasis (NCT01247818, NCT00941278) have been completed; results were not available at the time of publication.

**STF115469 (Vitamin D Analogue)**

STF115469 (GlaxoSmithKline) is a calcipotriene foam. At the time of publication, a randomized, placebo-controlled, double-blind, phase 3 trial (NCT01582932) of this vitamin D\(_3\) analogue with a projected enrollment of 180 participants was actively recruiting patients aged 2 to 11 years with mild to moderate plaque psoriasis to study the efficacy, safety, and tolerability of STF115469, as well as its pharmacokinetics and pharmacodynamics.

**WBI-1001 (Proprietary Product)**

WBI-1001 (Welichem Biotech Inc), or 2-isopropyl-5-[(E)-2-phenylethenyl] benzene-1,3-diol, is a novel proprietary agent that inhibits proinflammatory cytokines (eg, IFN-\(\gamma\), TNF-\(\alpha\)). A randomized, placebo-controlled, double-blind, phase 1 trial (NCT00830817) assessing the efficacy, safety, tolerability, and pharmacokinetics of WBI-1001 has been completed; results were not available at the time of publication. Another randomized, placebo-controlled, double-blind, phase 2 trial (NCT01098721) evaluating its efficacy and safety according to the physician’s global assessment demonstrated a therapeutic benefit of 62.8% in patients treated with WBI-1001 cream 1% versus 13.0% in those treated with a placebo after a 12-week treatment period (P<.0001).\(^11\) WBI-1001 may offer a novel approach in the treatment of mild to moderate psoriasis.

**Conclusion**

Enhanced knowledge of the underlying pathogeneses of psoriasis and psoriatic arthritis has identified new therapeutic targets and enabled the development of exciting novel treatments for these conditions. The topical agents currently in phase 2 and phase 3 clinical trials show promise in enhancing the way physicians treat psoriasis. There is hope for more individualized treatment regimens with improved tolerability and better safety profiles with increased therapeutic efficacy. As our understanding of the molecular underpinnings of psoriasis continues to deepen, it will afford the development of even more innovative therapeutics for use in the management of psoriasis.
REFERENCES


